Kate E. Mounsey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Kate E. Mounsey has a total of 138 co-authors. Here are the top co-authors by number of shared publications:
- Shelley F. Walton
Inflammation and Healing Research Cluster, School of Health and Sport Sciences, University of Sunshine Coast, Maroochydore DC, QLD, Australia
20 shared publications - James S. McCarthy
QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia
17 shared publications - Deborah C. Holt
Global and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Australia
13 shared publications - Bart J. Currie
Global and Tropical Health Division, Menzies School of Health Research, Charles Darwin University
7 shared publications - Tianfang Wang
School of Science, Technology and Engineering, University of the Sunshine Coast, Maroochydore, Australia
5 shared publications Bart J. Currie
Global and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia; Department of Infectious Diseases, Division of Medicine, Royal Darwin Hospital, Darwin, Northern Territory, Australia
4 shared publications
Latest Publications
- Open Access
- 5 November 2026
- Published by Frontiers Media SA in Frontiers in Insect Science
- Vol. 6, 1985870
Beyond chemical miticides: new frontiers against emerging genetic resistance in Varroa destructor mites in Australia
Varroa destructor mites parasitize Western and Eastern honey bees ( Apis mellifera and Apis cerana ) and drive significant colony losses worldwide. In Australia, the recent widespread establishment of Varroa threatens a A$14 billion (~US$10 billion) per annum honey bee industry and agricultural pollination services. Current synthetic miticides used to combat Varroa often target neurotransmitter receptors and ion channels, including pyrethroids (flumethrin, τ-fluvalinate) and amitraz. Alarmingly, Varroa with genetic resistance to both pyrethroids and amitraz have recently emerged in Australia. Beekeepers are now increasingly reliant on non-synthetic ‘soft’ miticides, which are often less effective and negatively impact colony health when used in the high temperatures common across much of Australia. New approaches are clearly needed to combat Varroa . One such next-generation technology is RNA interference (RNAi), in which double-stranded RNA (dsRNA) silences essential genes. RNAi can achieve high species specificity, has a more favorable human and environmental safety profile when appropriately designed, and is less susceptible to genetic resistance caused by target site alteration compared with chemical miticides. RNAi may also trigger immune responses in honey bees which help protect them from viral pathogens. In 2025, the first dsRNA treatment for Varroa (Norroa™) was commercialized in the United States. In silico and in vivo testing to date supports that Norroa™ is species-specific and effective in disrupting Varroa reproduction via targeting the calmodulin gene. However, the active component vadescana does not cause mite mortality and is therefore less effective in cases of high infestation, highlighting the need for other more effective dsRNAs. This review discusses the current state of Varroa control in Australia and exploration of potential dsRNA gene targets. We will discuss the necessary next steps for dsRNA miticide testing and propose new gene targets for further development.
- 5 November 2026
- Published by Frontiers Media SA in Frontiers in Insect Science
- Vol. 6, 1985870
Open AccessBeyond chemical miticides: new frontiers against emerging genetic resistance in Varroa destructor mites in Australia
Varroa destructor mites parasitize Western and Eastern honey bees ( Apis mellifera and Apis cerana ) and drive significant colony losses worldwide. In Australia, the recent widespread establishment of Varroa threatens a A$14 billion (~US$10 billion) per annum honey bee industry and agricultural pollination services. Current synthetic miticides used to combat Varroa often target neurotransmitter receptors and ion channels, including pyrethroids (flumethrin, τ-fluvalinate) and amitraz. Alarmingly, Varroa with genetic resistance to both pyrethroids and amitraz have recently emerged in Australia. Beekeepers are now increasingly reliant on non-synthetic ‘soft’ miticides, which are often less effective and negatively impact colony health when used in the high temperatures common across much of Australia. New approaches are clearly needed to combat Varroa . One such next-generation technology is RNA interference (RNAi), in which double-stranded RNA (dsRNA) silences essential genes. RNAi can achieve high species specificity, has a more favorable human and environmental safety profile when appropriately designed, and is less susceptible to genetic resistance caused by target site alteration compared with chemical miticides. RNAi may also trigger immune responses in honey bees which help protect them from viral pathogens. In 2025, the first dsRNA treatment for Varroa (Norroa™) was commercialized in the United States. In silico and in vivo testing to date supports that Norroa™ is species-specific and effective in disrupting Varroa reproduction via targeting the calmodulin gene. However, the active component vadescana does not cause mite mortality and is therefore less effective in cases of high infestation, highlighting the need for other more effective dsRNAs. This review discusses the current state of Varroa control in Australia and exploration of potential dsRNA gene targets. We will discuss the necessary next steps for dsRNA miticide testing and propose new gene targets for further development.
- Open Access
- 21 October 2024
- Published by Cambridge University Press (CUP) in Epidemiology and Infection
- Vol. 152, e129
A cross-sectional survey of knowledge and attitudes towards scabies control in Australian aged care facilities
Scabies outbreaks cause significant morbidity and disruption in aged care facilities and other institutional settings. Failure to manage scabies outbreaks may be attributable to low awareness amongst healthcare workers. A survey was distributed to healthcare workers across aged care facilities in South-East Queensland, Australia. The survey captured demographics, prior scabies experience, knowledge-based questions, and attitudes. Scabies was common in aged care facilities, with 41% of 128 respondents encountering the disease while working in aged care. Participants demonstrated sound theoretical knowledge regarding scabies (median knowledge score 82%). Scabies knowledge was not associated with years of experience in the sector or educational level but was associated with respondent age (p = 0.017). Knowledge gaps were evident regarding diagnosis, incubation periods, and treatment. Respondents demonstrated an inconsistent ability to identify atypical clinical presentations of scabies, showing discordance between theoretical knowledge and its practical application. The ability to identify crusted scabies was low, reflecting the high frequency of misdiagnosis of index cases in scabies outbreaks. Respondents considered scabies to be a problem and were supportive of improved management guidelines. These study outcomes will inform the design of accessible, targeted educational resources for scabies to help prevent and reduce the impact of outbreaks.
- 21 October 2024
- Published by Cambridge University Press (CUP) in Epidemiology and Infection
- Vol. 152, e129
Open AccessA cross-sectional survey of knowledge and attitudes towards scabies control in Australian aged care facilities
Scabies outbreaks cause significant morbidity and disruption in aged care facilities and other institutional settings. Failure to manage scabies outbreaks may be attributable to low awareness amongst healthcare workers. A survey was distributed to healthcare workers across aged care facilities in South-East Queensland, Australia. The survey captured demographics, prior scabies experience, knowledge-based questions, and attitudes. Scabies was common in aged care facilities, with 41% of 128 respondents encountering the disease while working in aged care. Participants demonstrated sound theoretical knowledge regarding scabies (median knowledge score 82%). Scabies knowledge was not associated with years of experience in the sector or educational level but was associated with respondent age (p = 0.017). Knowledge gaps were evident regarding diagnosis, incubation periods, and treatment. Respondents demonstrated an inconsistent ability to identify atypical clinical presentations of scabies, showing discordance between theoretical knowledge and its practical application. The ability to identify crusted scabies was low, reflecting the high frequency of misdiagnosis of index cases in scabies outbreaks. Respondents considered scabies to be a problem and were supportive of improved management guidelines. These study outcomes will inform the design of accessible, targeted educational resources for scabies to help prevent and reduce the impact of outbreaks.
- Top Cited Papers
- 3 October 2024
- Published by Springer Nature in Nature Reviews Disease Primers
- Vol. 10 (1) , 1-20
Scabies
Scabies is one of the most common and highest-burden skin diseases globally. Estimates suggest that >200 million people worldwide have scabies at any one time, with an annual prevalence of 455 million people, with children in impoverished and overcrowded settings being the most affected. Scabies infection is highly contagious and leads to considerable morbidity. Secondary bacterial infections are common and can cause severe health complications, including sepsis or necrotizing soft-tissue infection, renal damage and rheumatic heart disease. There is no vaccine or preventive treatment against scabies and, for the past 30 years, only few broad-spectrum antiparasitic drugs (mainly topical permethrin and oral ivermectin) have been widely available. Treatment failure is common because drugs have short half-lives and do not kill all developmental stages of the scabies parasite. At least two consecutive treatments are needed, which is difficult to achieve in resource-poor and itinerant populations. Another key issue is the lack of a practical, rapid, cheap and accurate diagnostic tool for the timely detection of scabies, which could prevent the cycle of exacerbation and disease persistence in communities. Scabies control will require a multifaceted approach, aided by improved diagnostics and surveillance, new treatments, and increased public awareness.
- 3 October 2024
- Published by Springer Nature in Nature Reviews Disease Primers
- Vol. 10 (1) , 1-20
Top Cited PapersScabies
Scabies is one of the most common and highest-burden skin diseases globally. Estimates suggest that >200 million people worldwide have scabies at any one time, with an annual prevalence of 455 million people, with children in impoverished and overcrowded settings being the most affected. Scabies infection is highly contagious and leads to considerable morbidity. Secondary bacterial infections are common and can cause severe health complications, including sepsis or necrotizing soft-tissue infection, renal damage and rheumatic heart disease. There is no vaccine or preventive treatment against scabies and, for the past 30 years, only few broad-spectrum antiparasitic drugs (mainly topical permethrin and oral ivermectin) have been widely available. Treatment failure is common because drugs have short half-lives and do not kill all developmental stages of the scabies parasite. At least two consecutive treatments are needed, which is difficult to achieve in resource-poor and itinerant populations. Another key issue is the lack of a practical, rapid, cheap and accurate diagnostic tool for the timely detection of scabies, which could prevent the cycle of exacerbation and disease persistence in communities. Scabies control will require a multifaceted approach, aided by improved diagnostics and surveillance, new treatments, and increased public awareness.
- Open Access
- 25 April 2024
- Published by Springer Nature in Parasites & Vectors
- Vol. 17 (1) , 1-9
Assessment of the in vitro acaricidal activity of Bravecto® (fluralaner) and a proposed orange oil-based formulation vehicle for the treatment of Sarcoptes scabiei
Background: Sarcoptic mange is a serious animal welfare concern in bare-nosed wombats (Vombatus ursinus). Fluralaner (Bravecto®) is a novel acaricide that has recently been utilised for treating mange in wombats. The topical ‘spot-on’ formulation of fluralaner can limit treatment delivery options in situ, but dilution to a volume for ‘pour-on’ delivery is one practicable solution. This study investigated the in vitro acaricidal activity of Bravecto, a proposed essential oil-based diluent (Orange Power®), and two of its active constituents, limonene and citral, againstSarcoptes scabiei.Methods: Sarcoptes scabieiwere sourced from experimentally infested pigs. In vitro assays were performed to determine the lethal concentration (LC50) and survival time of the mites when exposed to varying concentrations of the test solutions.Results: All compounds were highly effective at killing mites in vitro. The LC50values of Bravecto, Orange Power, limonene and citral at 1 h were 14.61 mg/ml, 4.50%, 26.53% and 0.76%, respectively. The median survival times of mites exposed to undiluted Bravecto, Orange Power and their combination were 15, 5 and 10 min, respectively. A pilot survival assay of mites collected from a mange-affected wombat showed survival times of < 10 min when exposed to Bravecto and Orange Power and 20 min when exposed to moxidectin.Conclusions: These results confirm the acaricidal properties of Bravecto, demonstrate acaricidal properties of Orange Power and support the potential suitability of Orange Power and its active constituents as a diluent for Bravecto. As well as killing mites via direct exposure, Orange Power could potentially enhance the topical delivery of Bravecto to wombats by increasing drug penetration in hyperkeratotic crusts. Further research evaluating the physiochemical properties and modes of action of Orange Power and its constituents as a formulation vehicle would be of value.Graphical
- 25 April 2024
- Published by Springer Nature in Parasites & Vectors
- Vol. 17 (1) , 1-9
Open AccessAssessment of the in vitro acaricidal activity of Bravecto® (fluralaner) and a proposed orange oil-based formulation vehicle for the treatment of Sarcoptes scabiei
Background: Sarcoptic mange is a serious animal welfare concern in bare-nosed wombats (Vombatus ursinus). Fluralaner (Bravecto®) is a novel acaricide that has recently been utilised for treating mange in wombats. The topical ‘spot-on’ formulation of fluralaner can limit treatment delivery options in situ, but dilution to a volume for ‘pour-on’ delivery is one practicable solution. This study investigated the in vitro acaricidal activity of Bravecto, a proposed essential oil-based diluent (Orange Power®), and two of its active constituents, limonene and citral, againstSarcoptes scabiei.Methods: Sarcoptes scabieiwere sourced from experimentally infested pigs. In vitro assays were performed to determine the lethal concentration (LC50) and survival time of the mites when exposed to varying concentrations of the test solutions.Results: All compounds were highly effective at killing mites in vitro. The LC50values of Bravecto, Orange Power, limonene and citral at 1 h were 14.61 mg/ml, 4.50%, 26.53% and 0.76%, respectively. The median survival times of mites exposed to undiluted Bravecto, Orange Power and their combination were 15, 5 and 10 min, respectively. A pilot survival assay of mites collected from a mange-affected wombat showed survival times of < 10 min when exposed to Bravecto and Orange Power and 20 min when exposed to moxidectin.Conclusions: These results confirm the acaricidal properties of Bravecto, demonstrate acaricidal properties of Orange Power and support the potential suitability of Orange Power and its active constituents as a diluent for Bravecto. As well as killing mites via direct exposure, Orange Power could potentially enhance the topical delivery of Bravecto to wombats by increasing drug penetration in hyperkeratotic crusts. Further research evaluating the physiochemical properties and modes of action of Orange Power and its constituents as a formulation vehicle would be of value.Graphical
- Open Access
- 1 April 2024
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 143, 107036
A systematic review of immunosuppressive risk factors and comorbidities associated with the development of crusted scabies
- 1 April 2024
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 143, 107036
Open AccessA systematic review of immunosuppressive risk factors and comorbidities associated with the development of crusted scabies
- Open Access
- 5 March 2023
- Published by Elsevier in International Journal for Parasitology: Drugs and Drug Resistance
- Vol. 21, 97-113
Pharmacokinetic and pharmacodynamic considerations for treating sarcoptic mange with cross-relevance to Australian wildlife
- 5 March 2023
- Published by Elsevier in International Journal for Parasitology: Drugs and Drug Resistance
- Vol. 21, 97-113
Open AccessPharmacokinetic and pharmacodynamic considerations for treating sarcoptic mange with cross-relevance to Australian wildlife
- Open Access
- 15 February 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1128688
Commentary: Transcriptome analysis of host inflammatory responses to the ectoparasitic mite Sarcoptes scabiei var. hominis
Commentary: Transcriptome analysis of host inflammatory responses to the ectoparasitic mite Sarcoptes scabiei var. hominis
- 15 February 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1128688
Open AccessCommentary: Transcriptome analysis of host inflammatory responses to the ectoparasitic mite Sarcoptes scabiei var. hominis
Commentary: Transcriptome analysis of host inflammatory responses to the ectoparasitic mite Sarcoptes scabiei var. hominis
- 1 March 2022
- Published by Springer Nature in Parasitology Research
- Vol. 121 (5) , 1551
Correction to: Drug dose and animal welfare: important considerations in the treatment of wildlife
- 1 March 2022
- Published by Springer Nature in Parasitology Research
- Vol. 121 (5) , 1551
Correction to: Drug dose and animal welfare: important considerations in the treatment of wildlife
- 11 February 2022
- Published by Springer Nature in Parasitology Research
- Vol. 121 (3) , 1065-1071
Drug dose and animal welfare: important considerations in the treatment of wildlife
A recent publication in Parasitology Research by (Old et al. Parasitol Res 120:1077–1090, 2021) raises the topical and often controversial issue of the treatment of wildlife by personnel with little or no formal scientific training (e.g. wildlife carers). In a valuable contribution to the subject, Old and colleagues document a wide range of topical (pour-on) application doses and frequencies of moxidectin (Cydectin®) administered in situ to bare-nosed wombats (Vombatus ursinus) by members of the wildlife carer/treater community in southeast Australia to treat sarcoptic mange disease. This treatment occurred under minor use permits issued by the Australian Pesticides and Veterinary Management Authority (APVMA). These permits do not require veterinary supervision, although carers are registered and are expected to comply with the guidelines of this permit.
- 11 February 2022
- Published by Springer Nature in Parasitology Research
- Vol. 121 (3) , 1065-1071
Drug dose and animal welfare: important considerations in the treatment of wildlife
A recent publication in Parasitology Research by (Old et al. Parasitol Res 120:1077–1090, 2021) raises the topical and often controversial issue of the treatment of wildlife by personnel with little or no formal scientific training (e.g. wildlife carers). In a valuable contribution to the subject, Old and colleagues document a wide range of topical (pour-on) application doses and frequencies of moxidectin (Cydectin®) administered in situ to bare-nosed wombats (Vombatus ursinus) by members of the wildlife carer/treater community in southeast Australia to treat sarcoptic mange disease. This treatment occurred under minor use permits issued by the Australian Pesticides and Veterinary Management Authority (APVMA). These permits do not require veterinary supervision, although carers are registered and are expected to comply with the guidelines of this permit.